A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 / idasanutlin in patients with metastatic castration resistant prostate cancer who have not previously received docetaxel. - MAdCaP

HS greater Glasgow and Clyde0 个研究点目标入组 132 人开始时间: 2014年3月31日最近更新: 2020年7月20日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 132

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Male

入选标准

•1. Histologically proven adenocarcinoma of the prostate with documented
•metastases (where the metastatic lesions are confined to 1 or 2 lesions on a bone scan these must be confirmed by a second modality (eg. CT, MRI or biopsy).
•2. Availability of archival tumour samples. Where patients are willing to undergo a biopsy as part of the study, these specimens may be used as an alternative where no archival specimen is available.
•3. Proven disease progression since last change in therapy defined by at least one of the following:
•a.PSA progression. This must be based on a series of at least 3 successively increasing readings each taken at least 7 days apart. The 3rd reading must be >= 2ng/ml. In the event where an intermediate reading is lower than a previous reading, then the patient will still be eligible (ie. the 3 readings do not need to be consecutive). The first of the three readings must have been obtained after commencing the previous systemic therapy, or, in the case of androgen receptor antagonists, after discontinuing.
•b. Radiographic progression since commencing last systemic anti-cancer therapy as defined by RECIST 1.1 (Eisenhauer et al. 2009 Eur J Cancer. 4 5:2 2 8) for non-bone disease or the appearance of 2 or more new lesions on a bone scan.
•4. Castrate levels of serum testosterone (<1.7nmol/l).
•5. On-going castration therapy.
•6. Male aged 18 or over.
•7. ECOG PS = 0 or 1.
•8. Hb>= 10g/dL; platelets >= 150 x 109/L; neutrophils >=1.5 x109/L.
•9. Bilirubin < 1.5 x ULN; ALT and/ or AST < 2.5 x ULN.
•10. Serum potassium =LLN; Alb = 30 g/L
•11.Serum creatinine < 1.5 x ULN or a calculated creatinine clearance = 60 mL/min
•12.Able to swallow study drugs.
•13.Life expectancy > 3 months.
•14.Provision of written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 32
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

排除标准

•1. Prior cytotoxic chemotherapy for castration resistant prostate cancer (patients may have received previous or ongoing bisphosphonates, eg. zoledronate, or denosumab).
•2. Prior ketoconazole, abiraterone, MDV3100 (enzalutamide), TAK-700 (orteronel) or other novel anti-hormonal.
•3. Uncontrolled hypertension (bp= 160 / 95 mmHg)
•4. Significant heart disease as evident by MI or arterial thrombotic events in past six months, severe unstable angina, or new york heart association class (NYHA) III or IV heart failure or class II to IV heart failure or cardic ejection fraction measurement of <50%.
•5. Other anticancer therapy (apart from LHRH agonist / antagonist) within 4 weeks (6 weeks for bicalutamide). This includes radiotherapy and therapeutic radionucleotides. Where patients are receiving bisphosphonates or denosumab they must have been on a stable dose for at least 6 weeks prior to starting study drug.
•6. The requirement for strong opiates to control cancer related pain in the two weeks before study entry (codeine and tramadol are permitted).
•7. Patient with a partner of child-bearing potential who is not using a highly effective method of contraception, who is unwilling to use condoms during the study and for 30 days after the last dose of study drug.
•8. Patients with known coagulopathy, platelet disorder or history of non-drug induced thrombocytopenia.
•9. Patients receiving oral or parenteral anti-coagulants/anti-platelet agents (chronic daily treatment with aspirin with doses >325 mg po daily, clopidogrel, low molecular weight heparin, or dagibatran, etc.) prior to the start of study therapy are excluded. Patients may receive anticoagulant flushes for maintenance of indwelling catheters.
•10. Patients with known bone marrow disorders which may interfere with bone marrow recovery (due to tumor involvement, fibrosis) (eg. Concomitant myelodysplastic syndrome)
•11. Patients who refuse blood products.

研究者

发起方

HS greater Glasgow and Clyde

相似试验

已完成

1 期

MAdCaP: MDM2 inhibition and Abiraterone in Carcinoma of the ProstateMalignant neoplasm of prostateCancerProstate cancer

ISRCTN38949950HS Greater Glasgow and Clyde (UK)132

进行中（未招募）

1 期

Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatment

EUCTR2012-004331-23-GBJanssen-Cilag International NV164

进行中（未招募）

1 期

Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2012-004331-23-HUJanssen-Cilag International NV144

进行中（未招募）

1 期

EUCTR2012-004331-23-BEJanssen-Cilag International NV144

进行中（未招募）

1 期

A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

EUCTR2012-004331-23-ITJanssen-Cilag International NV164